COLORADO SPRINGS, Colo., July 20 /PRNewswire-FirstCall/ -- Spectranetics Corporation announced today that the first patient was enrolled in the CELLO trial, which is an FDA-approved trial that will enroll 85 patients at up to 15 sites.
Click Here to read the entire article...